BioSpace News Archive

Aridis’ COVID-19 therapy is particularly exciting. AR-711 is an inhaled, self-administered, at-home treatment for mild-to-moderate SARS-CoV-2 infections.

New York-based TG Therapeutics announced positive topline results from two global Phase III clinical trials, ULTIMATE I and II, of ublituximab in relapsing forms of multiple sclerosis (RMS).

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

All eyes on the FDA as they review a COVID-19 vaccine, FDA approval of an Emergency Use Authorization to LabCorp’s home test kit for COVID-19, the first testing device that does not require a prescription and more news.

Gilead Sciences bolstered its capabilities in treating Hepatitis and other liver diseases with the €1.15 billion ($1.4 billion) cash acquisition of Germany-based Myr GmbH, a company focused on developing therapies for treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis.

Biopharma and life science companies and organizations strengthen their leadership teams and boards with these Movers & Shakers.

Cambridge-based Faze Medicines, the biotechnology company that develops therapeutics based on biomolecular condensates, announced today that it has raised $81 million in a Series A round of financing.

Viruses mutate, and SARS-CoV-2, the virus that causes COVID-19, is not different. Luckily, it appears to mutate relatively slowly. Meanwhile, researchers are beginning to get a grip on the virus’s evolution.

Pharma giant Boehringer Ingelheim strengthened its immuno-oncology portfolio this week by inking an acquisition deal with NBE Therapeutics for a tidy $1.4 billion US.

Intercept Pharmaceuticals is currently undergoing a leadership transition, with the company’s Chief Operating officer Jerome Durso taking the helm of the company as its newest President and Chief Executive Officer.